OptimizeRx Co. (NASDAQ:OPRX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of OptimizeRx Co. (NASDAQ:OPRX) have been given a consensus rating of “Moderate Buy” by the nine ratings firms that are covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $9.06.

A number of equities analysts have commented on the company. Royal Bank of Canada reissued a “sector perform” rating and issued a $6.00 price objective (down previously from $7.00) on shares of OptimizeRx in a research note on Wednesday, January 8th. Lake Street Capital reissued a “buy” rating and issued a $11.00 price objective on shares of OptimizeRx in a research note on Tuesday, December 24th. Stephens assumed coverage on OptimizeRx in a research note on Friday, December 20th. They issued an “equal weight” rating and a $5.50 price objective on the stock. B. Riley reduced their price objective on OptimizeRx from $17.00 to $13.00 and set a “buy” rating on the stock in a research note on Tuesday, December 24th. Finally, Stifel Nicolaus cut their price target on OptimizeRx from $13.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th.

Insider Activity

In related news, CEO William J. Febbo bought 20,000 shares of the business’s stock in a transaction on Thursday, December 12th. The shares were purchased at an average price of $5.01 per share, with a total value of $100,200.00. Following the completion of the purchase, the chief executive officer now owns 601,253 shares of the company’s stock, valued at $3,012,277.53. This represents a 3.44 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. 6.10% of the stock is currently owned by insiders.

Institutional Trading of OptimizeRx

Institutional investors and hedge funds have recently modified their holdings of the stock. SBI Securities Co. Ltd. bought a new position in OptimizeRx during the 4th quarter worth approximately $25,000. BNP Paribas Financial Markets grew its holdings in shares of OptimizeRx by 189.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock valued at $28,000 after buying an additional 2,414 shares during the period. SG Americas Securities LLC bought a new stake in shares of OptimizeRx in the 4th quarter valued at $51,000. Wells Fargo & Company MN raised its stake in OptimizeRx by 33.3% during the 4th quarter. Wells Fargo & Company MN now owns 11,208 shares of the company’s stock worth $54,000 after buying an additional 2,797 shares during the period. Finally, Quest Partners LLC lifted its holdings in OptimizeRx by 15,965.6% during the third quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock worth $76,000 after acquiring an additional 9,739 shares in the last quarter. 76.47% of the stock is owned by institutional investors.

OptimizeRx Price Performance

OptimizeRx stock opened at $5.78 on Friday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23. The firm has a market cap of $106.47 million, a P/E ratio of -4.35 and a beta of 1.38. The business’s fifty day moving average is $5.43 and its two-hundred day moving average is $6.25. OptimizeRx has a 52 week low of $3.78 and a 52 week high of $16.65.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.